Personalized Translational Platform for Biomarker Discovery in Brain Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

37 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-12-31

Study Completion Date

2016-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The central hypothesis for this proposal is that multimodal (clinical, imaging, tissue) biomarkers will better predict early brain tumor response to treatments and will be more reliable prognostic markers in patients with malignant brain tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Radiomics for Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy for Brain Metastases

NCT02265549

Metastases, Neoplasm

COMPLETED

MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy

NCT02031237

Brain Metastases

COMPLETED

Multicentre Validation of How Vascular Biomarkers From Tumor Can Predict the Survival of the Patient With Glioblastoma

NCT03439332

Glioblastoma

COMPLETED

Establishing Radiolabelled PSMA as a Target for Glioma Treatment

NCT05263466

Glioma, Malignant

NOT_YET_RECRUITING NA

Evaluation of FLT PET and MRI as Imaging Biomarkers of Early Treatment Response in Patients With Glioblastoma

NCT01880008

Glioblastoma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

High Grade Glioma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with high grade gliomas

All subjects will have radiographically suspected or surgically proven de novo high grade gliomas. There are no control patients.

FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT

Intervention Type DRUG

Each patient will have 0-3 or more FLT-PET brain scans.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT

Each patient will have 0-3 or more FLT-PET brain scans.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Newly diagnosed or suspected high grade glioma ≥ 1cm in diameter on postoperative anatomic imaging (contrast MRI), prior to initiation of chemoXRT
* Anticipated survival ≥6 months
* Able to give informed consent
* Capable of undergoing MRI and PET scans without the need for sedation or general anesthesia
* Male or Female

Exclusion Criteria

* Prior radiation therapy and chemotherapy to the brain
* Active intracranial infection or nonglial brain mass.
* Recent large intracranial hemorrhage (\<1 month)
* Expected survival \<6 months
* Pregnant or nursing
* Renal failure
* Lives far from BWH and/or is unwilling/ unable to return for scheduled imaging visits.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No